Core One Labs Extends Private Placement
Core One Labs Initiates $1.5 Million Private Placement
Core One Labs Signs Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin
Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
Core One Labs Says in Talks With Multiple Companies to Supply Psilocybin; COOL Gained 15% on Friday
Core One Labs (OTCMKTS:CLABD) Trading Up 1.9%
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization
Core One Labs Completes Synthetic Production of Psilocin at GMP Certified Manufacturing Facility; Surges Nearly 26% in Frankfurt Trading
Short Interest in Core One Labs Inc. (OTCMKTS:CLABF) Decreases By 42.9%
Core One Labs (OTCMKTS:CLABD) Trading Down 13.4%
Core One Labs (OTCMKTS:CLABD) Shares Down 4.5%
Core One Labs (OTCMKTS:CLABD) Trading Down 4.5%
Core One Labs Inc. (OTCMKTS:CLABF) Sees Significant Decrease in Short Interest
Core One Labs (OTCMKTS:CLABD) Stock Price Down 9.7%
Core One Labs Inc. (OTCMKTS:CLABF) Sees Significant Growth in Short Interest
Short Interest in Core One Labs Inc. (OTCMKTS:CLABF) Drops By 37.4%
Core One Labs (OTCMKTS:CLABD) Trading 17.2% Higher
Core One Labs (OTCMKTS:CLABF) Stock Price Down 23.1%
Core One Labs (OTCMKTS:CLABD) Shares Down 7.3%
European University to Fund Akome Biotech's Neurogenesis Stimulation Studies; Core One Labs Gained 15.5% on Friday